CERo Therapeutics Holdings, Inc.
CERO
$0.04
$0.008.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.31% | -24.80% | 9.99% | -23.75% | 66.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.26% | 10.46% | 5.50% | 12.19% | 86.90% |
| Operating Income | -116.26% | -10.46% | -5.50% | -12.19% | -86.90% |
| Income Before Tax | -775.79% | -14.86% | -121.23% | -122.02% | 153.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -775.79% | -14.86% | -121.23% | -122.02% | 153.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -775.79% | -14.86% | -121.23% | -122.02% | 153.11% |
| EBIT | -116.26% | -10.46% | -5.50% | -12.19% | -86.90% |
| EBITDA | -123.32% | -11.77% | -6.51% | -13.34% | -98.60% |
| EPS Basic | 93.13% | 94.66% | 3.26% | 47.61% | -- |
| Normalized Basic EPS | 99.17% | 97.74% | -- | 53.81% | -- |
| EPS Diluted | 93.13% | 94.66% | 3.26% | 47.61% | -- |
| Normalized Diluted EPS | 99.17% | 97.74% | -- | 53.81% | -- |
| Average Basic Shares Outstanding | 26,139.93% | 5,000.40% | -- | 9,396.04% | -- |
| Average Diluted Shares Outstanding | 26,139.93% | 5,000.40% | 1,187.86% | 9,396.04% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |